Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
2020 · New England Journal of Medicine · 15K citations
https://doi.org/10.1056/nejmoa2034577
N
Nicholas Kitchin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
66
Papers
23.2K
Citations
25
h-index
38
i10-index
Nicholas Kitchin is an academic researcher from Pfizer (United States). The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & Viral gastroenteritis research and epidemiology & Bacterial Infections and Vaccines. The author has an h-index of 25, co-authored 57 publications.
ORCID: 0000-0002-1808-3380Papers by this author
worksPhase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
2020 · Nature · 1,577 citations
https://doi.org/10.1038/s41586-020-2639-4
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
2021 · New England Journal of Medicine · 913 citations
https://doi.org/10.1056/nejmoa2107456
Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
2023 · New England Journal of Medicine · 175 citations
https://doi.org/10.1056/nejmc2214916
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
2023 · New England Journal of Medicine · 120 citations
https://doi.org/10.1056/nejmoa2213082
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old
2026 · Clinical Infectious Diseases · 0 citations
https://doi.org/10.1093/cid/ciag026
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat